Enterprise Value

1.599B

Cash

121.5M

Avg Qtr Burn

N/A

Short % of Float

12.93%

Insider Ownership

1.70%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Linzess® (linaclotide) Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder

Approved

Quarterly sales

Phase 3

Update

Phase 2

Data readout

IW-3300 Details
Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome

Phase 2

Data readout

Apraglutide (agonist of the GLP-2 receptor) Details
Short bowel syndrome with colon-in-continuity , Short bowel syndrome

Phase 2

Update

CNP-104 Details
Autoimmune disease, Primary biliary cholangitis, Liver disease

Phase 2a

Data readout

Linaclotide Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation

Failed

Discontinued